Drospirenone (Slynd)
Drospirenone
Lebasi Pharmaceuticals (Pty) Ltd
Registration
- Applicant
- Lebasi Pharmaceuticals (Pty) Ltd
- Registrations
- 1
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Slynd EACH TABLET CONTAINS DROSPIRENONE 4,0 mg | Not listed | 56036756/21.8.2/0367 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Drospirenone
- when intended for hormone replacement therapy;
- except when intended for oral contraception. (S3)
Consolidated Schedules 06 July 2026, lines 6127 to 6131
S3: Drospirenone
- when intended for oral contraception;
- except when intended for hormone replacement therapy. (S4)
Consolidated Schedules 06 July 2026, lines 3490 to 3494
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
(1R,2R,4R,10R,11S,14S,15S,16S,18S,19S)-10,14-Dimethylspiro[hexacyclo[9.8.0.02,4.05,10.014,19.016,18]nonadec-5-ene-15,5'-oxolane]-2',7-dione
Drag to rotate. Structure from PubChem CID 68873.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.